ATA328286A - Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa - Google Patents

Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa

Info

Publication number
ATA328286A
ATA328286A AT0328286A AT328286A ATA328286A AT A328286 A ATA328286 A AT A328286A AT 0328286 A AT0328286 A AT 0328286A AT 328286 A AT328286 A AT 328286A AT A328286 A ATA328286 A AT A328286A
Authority
AT
Austria
Prior art keywords
aeruginosa
kit
determining
cell lines
monoclonal antibodies
Prior art date
Application number
AT0328286A
Other languages
English (en)
Other versions
AT400441B (de
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Publication of ATA328286A publication Critical patent/ATA328286A/de
Application granted granted Critical
Publication of AT400441B publication Critical patent/AT400441B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0328286A 1985-12-10 1986-12-10 Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa AT400441B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80739485A 1985-12-10 1985-12-10
US93117986A 1986-11-24 1986-11-24

Publications (2)

Publication Number Publication Date
ATA328286A true ATA328286A (de) 1995-05-15
AT400441B AT400441B (de) 1995-12-27

Family

ID=27123006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0328286A AT400441B (de) 1985-12-10 1986-12-10 Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa

Country Status (21)

Country Link
US (4) US5378812A (de)
JP (1) JPH07116237B2 (de)
KR (1) KR910008361B1 (de)
CN (1) CN86108380A (de)
AT (1) AT400441B (de)
BE (1) BE905890A (de)
CH (1) CH677362A5 (de)
DE (1) DE3642095C2 (de)
DK (1) DK594586A (de)
FI (1) FI86377C (de)
FR (1) FR2593826B1 (de)
GB (1) GB2185266B (de)
HU (1) HUT41836A (de)
IE (1) IE59741B1 (de)
IT (1) IT1199735B (de)
LU (1) LU86711A1 (de)
NL (1) NL8603132A (de)
NO (1) NO178718C (de)
NZ (1) NZ218499A (de)
PT (1) PT83894B (de)
SE (1) SE468831B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
EP0256713A3 (de) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutische, menschliche Antipseudomonas-Aeruginosa-Antikörper
EP0327648B1 (de) * 1986-12-15 1993-06-09 MITSUI TOATSU CHEMICALS, Inc. Menschlicher monoklonaler antikörper und arzneimittel zur prophylaxe und behandlung von infektiösen krankheiten
US5521085A (en) * 1986-12-15 1996-05-28 Mitsui Toatsu Chemicals, Inc. Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
JPH01197500A (ja) * 1988-01-29 1989-08-09 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
GB2218703B (en) * 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
CA1341375C (en) * 1988-10-12 2002-07-09 Baxter International Inc. Compositions and methods for the treatment and prevention of gram-negative bacterial infections
EP0382031A3 (de) * 1989-02-10 1991-06-26 Miles Inc. Monoklonal-Antikörper in einer Zusammensetzung von Globulin aus Immunserum
US4994269A (en) * 1989-03-17 1991-02-19 Miles Inc. Topical use of antibodies for prevention or treatment of pseudomonas infections
FI905644A0 (fi) * 1989-03-20 1990-11-14 Mitsui Toatsu Chemicals Med pseudomonas aeruginosa reaktiva maenniskans monoklonala motkroppar, celler som kan producera dessa, foerfaranden foer framstaellning av dessa och farmaceutiska preparat innehaollande dessa.
JPH02283294A (ja) * 1989-04-24 1990-11-20 Sumitomo Chem Co Ltd ヒトモノクローナル抗体
JPH0329196A (ja) * 1989-05-09 1991-02-07 Advanced Micro Devicds Inc センス増幅器
US5858728A (en) * 1991-03-13 1999-01-12 Common Services Agency Monoclonal antibody against LPS core
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
WO2003063693A2 (en) * 2002-01-31 2003-08-07 Expressive Constructs, Inc. Method for detecting microorganisms
US20060292562A1 (en) * 2002-05-29 2006-12-28 Pollard Harvey B Methods of identifying genomic and proteomic biomarkers for cystic fibrosis, arrays comprising the biomarkers and methods of using the arrays
BR0215954A (pt) 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
CA2514938A1 (en) * 2003-01-31 2004-10-14 Ethicon, Inc. Method for detecting escherichia coli
EP1692510B1 (de) 2003-11-03 2008-01-02 Ethicon, Inc. Verfahren, peptide und biosensoren mit eignung zum nachweis eines breiten spektrums von bakterien
EP1690875A1 (de) * 2005-02-14 2006-08-16 Kenta Biotech AG Menschlicher Monoklonaler Antikörper, welcher spezifisch für lipopolysaccharide (LPS) von Pseudomonas aeruginosa IATS O11 ist
AU2007245258B2 (en) * 2006-05-01 2013-09-19 Bioness Neuromodulation Ltd. Improved functional electrical stimulation systems
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
US20130022604A1 (en) * 2010-02-18 2013-01-24 Symphogen A/S Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
JPS59137497A (ja) * 1983-01-20 1984-08-07 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
JPS58216125A (ja) * 1982-06-09 1983-12-15 Asahi Chem Ind Co Ltd ヒト抗体の産生方法
JPS5929622A (ja) * 1982-08-10 1984-02-16 Meiji Seika Kaisha Ltd モノクロ−ナル抗体、その製造法およびその用途
WO1984004458A1 (en) * 1983-05-06 1984-11-22 Matthew Pollack Monoclonal antibodies reactive with endotoxin core
US4587121A (en) * 1983-06-14 1986-05-06 Miles Laboratories, Inc. High titer Pseudomonas immune serum globulin
US5179018A (en) * 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4683196A (en) * 1983-12-12 1987-07-28 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
WO1985002685A1 (en) * 1983-12-12 1985-06-20 Meru, Inc. Method and materials for the identification of lipopolysaccharide producing microorganisms
JPS60248625A (ja) * 1984-05-25 1985-12-09 Mitsui Toatsu Chem Inc 抗緑膿菌モノクロ−ナル抗体、その製法ならびに用途
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
EP0233289B1 (de) * 1984-12-26 1993-03-10 Teijin Limited Humaner monoklonaler antikörper gegen pseudomonas aeruginosagegen pseudomonas aeruginosa produzierende hybridomen
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
JPS6229175A (ja) * 1985-07-29 1987-02-07 Nippon Telegr & Teleph Corp <Ntt> 電界効果型トランジスタの製造方法
DE3689713T2 (de) * 1985-08-01 1994-07-07 Miles Inc Schützende Antikörper gegen serotypische Determinanten von flagellären Antigenen.
US4772464A (en) * 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4777136A (en) * 1985-09-27 1988-10-11 The Regents Of The University Of California Monoclonal antibody reactive with Pseudomonas Aeruginosa
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
DK172840B1 (da) * 1986-07-03 1999-08-09 Genetic Systems Corp Monoklonale antistoffer mod Pseudomonas aeruginosa flagella, farmaceutiske præparater indeholdende sådanne antistoffer og c
EP0256713A3 (de) * 1986-08-06 1989-02-15 Merck & Co. Inc. Therapeutische, menschliche Antipseudomonas-Aeruginosa-Antikörper

Also Published As

Publication number Publication date
FI86377C (fi) 1992-08-25
IT1199735B (it) 1988-12-30
IT8622630A0 (it) 1986-12-10
FR2593826A1 (fr) 1987-08-07
NL8603132A (nl) 1987-07-01
DE3642095A1 (de) 1987-07-02
US5662905A (en) 1997-09-02
KR870005648A (ko) 1987-07-06
FI865027A7 (fi) 1987-06-11
JPH07116237B2 (ja) 1995-12-13
AT400441B (de) 1995-12-27
PT83894A (en) 1987-01-01
FI865027A0 (fi) 1986-12-10
US5627067A (en) 1997-05-06
JPS62187417A (ja) 1987-08-15
NO864971L (no) 1987-06-11
GB2185266A (en) 1987-07-15
SE8605295D0 (sv) 1986-12-10
SE468831B (sv) 1993-03-29
CH677362A5 (de) 1991-05-15
DE3642095C2 (de) 1998-10-01
SE8605295L (sv) 1987-06-11
KR910008361B1 (ko) 1991-10-12
BE905890A (fr) 1987-06-10
NO178718B (no) 1996-02-12
GB2185266B (en) 1990-09-05
NZ218499A (en) 1990-04-26
NO178718C (no) 1996-05-22
NO864971D0 (no) 1986-12-10
GB8629540D0 (en) 1987-01-21
FI86377B (fi) 1992-05-15
DK594586A (da) 1987-06-11
LU86711A1 (fr) 1988-07-14
CN86108380A (zh) 1987-10-28
IE863230L (en) 1987-06-10
US5378812A (en) 1995-01-03
PT83894B (pt) 1989-07-31
FR2593826B1 (fr) 1990-11-16
IE59741B1 (en) 1994-03-23
DK594586D0 (da) 1986-12-10
US5628996A (en) 1997-05-13
HUT41836A (en) 1987-05-28

Similar Documents

Publication Publication Date Title
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
DE3880372D1 (de) Verfahren und geraet zur bestimmung des alkoholspiegels von personen.
DE3850452D1 (de) Gekrümmte polykarbonatgeschützte Polarisationsschicht und Verfahren zur Herstellung.
DE3876273D1 (de) Isoelektrisches fokussierverfahren sowie einrichtung zur durchfuehrung dieses verfahrens.
DE3583576D1 (de) Kuenstliches blutgefaess und verfahren zur herstellung.
DE68928612D1 (de) Verfahren zur bestimmung der inferenzregel sowie inferenzmotor
DE3585938D1 (de) Ultraschallwandler und verfahren zur herstellung desselben.
DE3574827D1 (de) Verfahren zur herstellung von sekundaeren und primaeren aminen.
DE3689218D1 (de) Verfahren zur differenzierten Bestimmung weisser Blutkörperchen.
DE68913394D1 (de) Verfahren zur Herstellung von substituierten Phenoxyethylaminen sowie Zwischenverbindungen.
ATE10013T1 (de) Verfahren und reagens zur bestimmung von glycerin.
DE3888998D1 (de) Verfahren zur Bestimmung eines Antikörpers in menschlichen Körperflüssigkeiten.
ATA337285A (de) Verfahren zur herstellung von isosilybinfreiem silibinin
DE3583875D1 (de) Verfahren zur herstellung von kugelfoermigen vollblut-erythrocyten und fixierung derselben.
DE3875825D1 (de) Verfahren zur bestimmung der absorption von thyroxin.
DE3583891D1 (de) Monoklonaler menschlicher anti-igg-koerper und verfahren zu seiner herstellung.
DE3684511D1 (de) Verfahren zur herstellung von l-threonin und l-isoleucin.
AT372856B (de) Verfahren zur herstellung von humanem relaxin
DE3787706D1 (de) Verfahren zur quantitativen Bestimmung der Antigene und Antikörper.
DE69026611D1 (de) Verfahren zur Bestimmung von Fruktosaminen
DE3585238D1 (de) Verfahren zur bestimmung des reduzierten zustands von nicotinamid-adenin-dinukleotid.
AT379815B (de) Verfahren zur herstellung von (e)-5(2-bromvinyl)- uridins und seiner derivate
DE3684632D1 (de) Tonerzusammensetzung und verfahren zur herstellung.
AT384544B (de) Verfahren zur bestimmung der beweglichkeit von koerperteilen
DE3580120D1 (de) Laeufer und verfahren zur herstellung solcher laeufer.

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee